Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Lenalidomide with rituximab for mantle cell lymphoma

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 11.12.17
Views: 2888

Prof Jia Ruan - Weill Cornell Medicine and New York Presbyterian Hospital, New York, USA

Prof Ruan speaks with ecancer at the ASH 217 annual meeting about 5 year follow-up data from a trial of immunomodulatory induction therapy for mantle cell lymphoma patients.

The median age among the 38 patients involved in this trial was 65.

She describes the results as consistent with existing safety, efficacy and survival data from a 2015 interim analysis, and describes the management of adverse events including infections and neutropenia.

Prof Ruan notes that, our of patients who developed secondary malignancies, skin diseases were the most common, and that a history of skin cancer was not an exclusion criteria for patients entering the trial so long as they were not receiving current therapies.

Overall, Prof Ruan looks forward to future trials incorporating immune therapies into new combinations to tackle MCL.

ecancer's filming has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.

Related videos

follow us

Donate to ecancer

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation